Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;12(9):517-31.
doi: 10.1038/nrrheum.2016.92. Epub 2016 Jun 23.

Autophagy: controlling cell fate in rheumatic diseases

Affiliations
Review

Autophagy: controlling cell fate in rheumatic diseases

Jason S Rockel et al. Nat Rev Rheumatol. 2016 Sep.

Erratum in

Abstract

Autophagy, an endogenous process necessary for the turnover of organelles, maintains cellular homeostasis and directs cell fate. Alterations to the regulation of autophagy contribute to the progression of various rheumatic diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), osteoarthritis (OA) and systemic sclerosis (SSc). Implicit in the progression of these diseases are cell-type-specific responses to surrounding factors that alter autophagy: chondrocytes within articular cartilage show decreased autophagy in OA, leading to rapid cell death and cartilage degeneration; fibroblasts from patients with SSc have restricted autophagy, similar to that seen in aged dermal fibroblasts; fibroblast-like synoviocytes from RA joints show altered autophagy, which contributes to synovial hyperplasia; and dysregulation of autophagy in haematopoietic lineage cells alters their function and maturation in SLE. Various upstream mechanisms also contribute to these diseases by regulating autophagy as part of their signalling cascades. In this Review, we discuss the links between autophagy, immune responses, fibrosis and cellular fates as they relate to pathologies associated with rheumatic diseases. Therapies in clinical use, and in preclinical or clinical development, are also discussed in relation to their effects on autophagy in rheumatic diseases.

PubMed Disclaimer

References

    1. Nat Rev Rheumatol. 2011 Jan;7(1):33-42 - PubMed
    1. Cancer Immunol Immunother. 2015 Apr;64(4):437-46 - PubMed
    1. Lupus. 2016 Jun;25(7):699-709 - PubMed
    1. Oncol Lett. 2014 Apr;7(4):1057-1062 - PubMed
    1. Immunol Rev. 2010 Jan;233(1):34-54 - PubMed

MeSH terms

Substances

Grants and funding

LinkOut - more resources